Apollomics, Inc. (APLM) vs INmune Bio, Inc. (INMB)
A side-by-side comparison of Apollomics, Inc. and INmune Bio, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
APLM
Apollomics, Inc.
$25.00HealthcareDelayed quote: Oct 6, 2026, 10:04 AM EDT
INMB
INmune Bio, Inc.
$1.93HealthcareDelayed quote: Oct 6, 2026, 10:05 AM EDT
Total return — APLM vs INMB
growth of $100 · dividends reinvested · last 5yAPLM -97.6% (-52.8%/yr)INMB -85.4% (-32.0%/yr)INMB compounded faster over this window
Log scale — wide-divergence pair
APLM INMB
APLM vs INMB: by the numbers
- •APLM is the larger company ($55M vs $51M market cap).
- •Both run net losses; APLM's is the smaller (-128.69% vs -91866.00% net margin).
Metrics side by side
Valuation
| Metric | APLM | INMB |
|---|---|---|
| P/B ratio | N/A | 2.52 |
Profitability
| Metric | APLM | INMB |
|---|---|---|
| Gross margin | 97.00% | 100.00% |
| Operating margin | -111.45% | -61738.00% |
| Net margin | -128.69% | -91866.00% |
| ROE | N/A | -90.44% |
| ROIC | -2441.49% | -96.37% |
Growth (annualized)
| Metric | APLM | INMB |
|---|---|---|
| Revenue CAGR (5Y) | 35.84% | N/A |
| Total return CAGR (5Y) | N/A | -36.88% |
Go deeper
Dig into the metrics
Apollomics ROEINmune Bio ROEApollomics operating marginINmune Bio operating marginApollomics revenue growthINmune Bio revenue growthApollomics free cash flowINmune Bio free cash flow
Apollomics & INmune Bio appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.